Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2FLDJ)

• Drug Name: Alstiphyllanine D Drug Info
• Synonyms: Alstiphyllanine D; CHEMBL540945

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 45269680
  TTD Drug ID: DM2FLDJ
  VARIDT Drug ID: DR00889

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium/glucose cotransporter 1 (SGLT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sotagliflozin	DMMLXA9	Heart failure	BD10-BD13	Approved	[2]
LIK-066	DM32NWD	Heart failure	BD10-BD13	Phase 2	[3]
YG1699	DM1NR1J	Type-1 diabetes	5A10	Phase 2	[4]
1614235 + 2330672	DMD751X	Type-2 diabetes	5A11	Phase 1	[3]
GSK1614235	DM7I1AQ	Type-2 diabetes	5A11	Phase 1	[5]
LX2761	DM8ZS7T	Type 2 diabetes	5A11	Phase 1	[6]
T-1095	DMGFS51	Diabetic complication	5A2Y	Discontinued in Phase 2	[7]
KURAIDIN	DMLDUJ1	Discovery agent	N.A.	Investigative	[8]
KURARINONE	DMH0G8W	Discovery agent	N.A.	Investigative	[8]
10-methoxy-N(1)-methylburnamine-17-O-veratrate	DMJW25X	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting SLC5A2 messenger RNA (SLC5A2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bexagliflozin	DMK56G0	Type 2 diabetes	5A11	Approved	[9]
ISIS-SGLT2	DMDKAIC	Type-2 diabetes	5A11	Phase 1	[10]
KURAIDIN	DMLDUJ1	Discovery agent	N.A.	Investigative	[8]
KURARINONE	DMH0G8W	Discovery agent	N.A.	Investigative	[8]
10-methoxy-N(1)-methylburnamine-17-O-veratrate	DMJW25X	Discovery agent	N.A.	Investigative	[1]
Alstiphyllanine F	DMKRAEW	Discovery agent	N.A.	Investigative	[1]
Kushenol N	DMY13UR	Discovery agent	N.A.	Investigative	[8]
Alstiphyllanine E	DMTNQ5E	Discovery agent	N.A.	Investigative	[1]
Burnamine-17-O-3',4',5'-trimethoxybenzoate	DMBO0WI	Discovery agent	N.A.	Investigative	[1]
O-spiroketal glucoside	DM3FS62	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SLC5A2 messenger RNA (SLC5A2 mRNA)	TTF8JAT	SC5A2_HUMAN	Inhibitor	[1]
Sodium/glucose cotransporter 1 (SGLT1)	TT2UE56	SC5A1_HUMAN	Inhibitor	[1]

References

• [1] Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
• [2] LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).
• [4] ClinicalTrials.gov (NCT04956263) A Comparison of Postprandial Glucose After a Mixed Meal Tolerance Test, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study of the Dual Systemic SGLT1 and SGLT2 Inhibitor YG1699, and the Selective SGLT2 Inhibitor Dapagliflozin in Subjects With Type 1 Diabetes. U.S.National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [6] Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals.
• [7] T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.
• [8] Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [11] ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32.